![](https://investorshub.advfn.com/uicon/756666.png?cb=1598094430)
Thursday, August 27, 2020 8:17:23 PM
"In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer’s disease, Parkinson’s disease, and Autism Spectrum Disorders."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967653/pdf/nihms231918.pdf
Now... Aviptadil/RLF-100 is a proprietary form of VIP and we own the patents to it AND to the process of synthesizing it. Perhaps Aviptadil will be developed into a broader product line post-Covid. I could see myself holding some shares bought under $0.50 until I'm old, and one day I'll print my shares on some fancy paper and show them to my grandchildren :)
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM